Top

Journal of Translational Medicine

Published in:

Open Access 01-12-2011 | Research

Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma

Authors: Sheng-Hua Chu, Dong-Fu Feng, Yan-Bin Ma, Hong Zhang, Zhi-An Zhu, Zhi-Qiang Li, Pu-Cha Jiang

Published in: Journal of Translational Medicine | Issue 1/2011

Abstract

Background

Downregulation of the putative tumor suppressor gene SLC22A18 has been reported in a number of human cancers. The aim of this study was to investigate the relationship between SLC22A18 downregulation, promoter methylation and the development and progression of human glioma.

Method

SLC22A18 expression and promoter methylation was examined in human gliomas and the adjacent normal tissues. U251 glioma cells stably overexpressing SLC22A18 were generated to investigate the effect of SLC22A18 on cell growth and adherence in vitro using the methyl thiazole tetrazolium assay. Apoptosis was quantified using flow cytometry and the growth of SLC22A18 overexpressing U251 cells was measured in an in viv o xenograft model.

Results

SLC22A18 protein expression is significantly decreased in human gliomas compared to the adjacent normal brain tissues. SLC22A18 protein expression is significantly lower in gliomas which recurred within six months after surgery than gliomas which did not recur within six months. SLC22A18 promoter methylation was detected in 50% of the gliomas, but not in the adjacent normal tissues of any patient. SLC22A18 expression was significantly decreased in gliomas with SLC22A18 promoter methylation, compared to gliomas without methylation. The SLC22A18 promoter is methylated in U251 cells and treatment with the demethylating agent 5-aza-2-deoxycytidine increased SLC22A18 expression and reduced cell proliferation. Stable overexpression of SLC22A18 inhibited growth and adherence, induced apoptosis in vitro and reduced in vivo tumor growth of U251 cells.

Conclusion

SLC22A18 downregulation via promoter methylation is associated with the development and progression of glioma, suggesting that SLC22A18 is an important tumor suppressor in glioma.

Available only for authorised users

Chu SH, Feng DF, Zhang H, Chen ET, Duan ZX, Li XY, Li J, Ma YB, Zhu ZA, Qiu JH: c-Met-targeted RNA interference inhibits growth and metastasis of glioma U251 cells in vitro. J Neurooncol. 2009, 93: 183-9. 10.1007/s11060-008-9772-5.CrossRefPubMed

Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, Perry SR, Tonon G, Chu GC, Ding Z, Stommel JM, Dunn KL, Wiedemeyer R, You MJ, Brennan C, Wang YA, Ligon KL, Wong WH, Chin L, DePinho RA: p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature. 2008, 455: 1129-33. 10.1038/nature07443.PubMedCentralCrossRefPubMed

Zagzag D, Lukyanov Y, Lan L, Ali MA, Esencay M, Mendez O, Yee H, Voura EB, Newcomb EW: Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest. 2006, 86: 1221-32. 10.1038/labinvest.3700482.CrossRefPubMed

Chu SH, Ma YB, Feng DF, Zhang H, Qiu JH, Zhu ZA: c-Met antisense oligodeoxynucleotides increase sensitivity of human glioma cells to paclitaxel. Oncol Rep. 2010, 24: 189-94.CrossRefPubMed

D Lee MP, Reeves C, Schmitt A, Su K, Connors TD, Hu RJ, Brandenburg S, Lee MJ, Miller G, Feinberg AP: Somatic mutation of TSSC5, a novel imprinted gene from human chromosome 11p15.5. Cancer Res. 1998, 58: 4155-9.

Schwienbacher C, Sabbioni S, Campi M, Veronese A, Bernardi G, Menegatti A, Hatada I, Mukai T, Ohashi H, Barbanti-Brodano G, Croce CM, Negrini M: Transcriptional map of 170-kb region at chromosome 11p15.5: identification and mutational analysis of the BWR1A gene reveals the presence of mutations in tumor samples. Proc Natl Acad Sci USA. 1998, 95: 3873-8. 10.1073/pnas.95.7.3873.PubMedCentralCrossRefPubMed

Yamada HY, Gorbsky GJ: Tumor suppressor candidate TSSC5 is regulated by UbcH6 and a novel ubiquitin ligase RING105. Oncogene. 2006, 25: 1330-9. 10.1038/sj.onc.1209167.PubMedCentralCrossRefPubMed

Albrecht S, Hartmann W, Houshdaran F, Koch A, Gärtner B, Prawitt D, Zabel BU, Russo P, Von Schweinitz D, Pietsch T: Allelic loss but absence of mutations in the polyspecific transporter gene BWR1A on 11p15.5 in hepatoblastoma. Int J Cancer. 2004, 111: 627-32. 10.1002/ijc.20280.CrossRefPubMed

Mohammad F, Mondal T, Guseva N, Pandey GK, Kanduri C: Kcnq1ot1 noncoding RNA mediates transcriptional gene silencing by interacting with Dnmt1. Development. 2010, 137: 2493-2499. 10.1242/dev.048181.CrossRefPubMed

10.

Gallagher E, Mc Goldrick A, Chung WY, Mc Cormack O, Harrison M, Kerin M, Dervan PA, Mc Cann A: Gain of imprinting of SLC22A18 sense and antisense transcripts in human breast cancer. Genomics. 2006, 88: 12-7. 10.1016/j.ygeno.2006.02.004.CrossRefPubMed

11.

Wang S, Liu H, Ren L, Pan Y, Zhang Y: Inhibiting colorectal carcinoma growth and metastasis by blocking the expression of VEGF using RNA interference. Neoplasia. 2008, 10: 399-407.PubMedCentralCrossRefPubMed

12.

13.

Uemura K, Takao S, Aikou T: In vitro determination of basement membrane invasion predicts liver metastases in human gastrointestinal carcinoma. Cancer Res. 1998, 58: 3727-31.PubMed

14.

Jin M, He S, Wörpel V, Ryan SJ, Hinton DR: Promotion of adhesion and migration of RPE cells to provisional extracellular matrices by TNF-alpha. Invest Ophthalmol Vis Sci. 2000, 41: 4324-32.PubMed

15.

Wang SM, Zhu J, Pan LF, Liu YK: Inhibitory effect of dimeric β peptide on the recurrence and metastasis of hepatocellular carcinoma in vitro and in mice. World J Gastroenterol. 2008, 14: 3054-8. 10.3748/wjg.14.3054.PubMedCentralCrossRefPubMed

16.

Xu HM, Zhang HW, He HY, Hou YY, Zhao ZQ: Methylation and mRNA expression of imprinted gene SLC22A18/TSSC5/BWR1A in breast cancer (in Chinese). Chin J Pathophysiol. 2008, 24: 1007-12.

17.

Chu SH, Yuan XH, Li ZQ, Jiang PC, Zhang J: C-Met antisense oligodeoxynucleotide inhibits growth of glioma cells. Surg Neurol. 2006, 65: 533-538. 10.1016/j.surneu.2005.11.024.CrossRefPubMed

18.

Gutmann DH, Huang ZY, Hedrick NM, Ding H, Guha A, Watson MA: Mouse glioma gene expression profiling identifies novel human glioma-associated genes. Ann Neurol. 2002, 51: 393-405. 10.1002/ana.10145.CrossRefPubMed

19.

Dong Y, Jia L, Wang X, Tan X, Xu J, Deng Z, Jiang T, Rainov NG, Li B, Ren H: Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells. Int J Oncol. 2011, 38: 555-69.PubMed

20.

Hu J, Jiang C, Ng HK, Pang JC, Tong CY, Chen S: Genome-wide allelotype study of primary glioblastoma multiforme. Chin Med J (Engl). 2003, 116: 577-83.

21.

Squatrito M, Brennan CW, Helmy K, Huse JT, Petrini JH, Holland EC: Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell. 2010, 18: 619-29. 10.1016/j.ccr.2010.10.034.CrossRefPubMed

22.

Noble M, Mayer-Pröschel M: Growth factors, glia and gliomas. J Neurooncol. 1997, 35: 193-209. 10.1023/A:1005898228116.CrossRefPubMed

23.

Holland EC, Hively WP, DePinho RA, Varmus HE: A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev. 1998, 12: 3675-85. 10.1101/gad.12.23.3675.PubMedCentralCrossRefPubMed

24.

Liu C, Sage JC, Miller MR, Verhaak RG, Hippenmeyer S, Vogel H, Foreman O, Bronson RT, Nishiyama A, Luo L, Zong H: Mosaic Analysis with Double Markers Reveals Tumor Cell of Origin in Glioma. Cell. 2011, 146: 209-21. 10.1016/j.cell.2011.06.014.PubMedCentralCrossRefPubMed

25.

Li Y, Meng G, Guo QN: Changes in genomic imprinting and gene expression associated with transformation in a model of human osteosarcoma. Exp Mol Pathol. 2008, 84: 234-239. 10.1016/j.yexmp.2008.03.013.CrossRefPubMed

26.

Bajaj V, Singhmar P, Kumar A: Promoter characterization and regulation of expression of an imprinted gene SLC22A18AS. Gene. 2008, 424: 40-47. 10.1016/j.gene.2008.07.032.CrossRefPubMed

27.

Ali AM, Bajaj V, Gopinath KS, Kumar A: Characterization of the human SLC22A18 gene promoter and its regulation by the transcription factor Sp1. Gene. 2009, 429: 37-43. 10.1016/j.gene.2008.10.004.CrossRefPubMed

Title: Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma
Authors: Sheng-Hua Chu
Dong-Fu Feng
Yan-Bin Ma
Hong Zhang
Zhi-An Zhu
Zhi-Qiang Li
Pu-Cha Jiang
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: Journal of Translational Medicine / Issue 1/2011
Electronic ISSN: 1479-5876
DOI: https://doi.org/10.1186/1479-5876-9-156

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma

Abstract

Background

Method

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2011

Genetic mutations in non-syndromic deafness patients of uyghur and han chinese ethnicities in xinjiang, China: a comparative study

15 kDa Granulysin versus GM-CSF for monocytes differentiation: analogies and differences at the transcriptome level

EGFR-specific T cell frequencies correlate with EGFR expression in head and neck squamous cell carcinoma

Hybrid approach of ventricular assist device and autologous bone marrow stem cells implantation in end-stage ischemic heart failure enhances myocardial reperfusion

Glycyrrhizin as antiviral agent against Hepatitis C Virus

Personalized medicine: a patient - centered paradigm

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page